Literature DB >> 16806173

Does increased excitatory drive from the subthalamic nucleus contribute to dopaminergic neuronal death in Parkinson's disease?

M Rosario Luquin1, Laura Saldise, Javier Guillén, Silvia Belzunegui, Waldy San Sebastián, Amaya Izal, Pablo Garrido, Marianne Vázquez.   

Abstract

Excitotoxicity has been suggested to play a pivotal role in the pathogenesis of Parkinson disease (PD). As subthalamic nucleus (STN) neurons express glutamate and are overactivated in parkinsonism, it seems that in PD dopaminergic (DA) neurons are under the influence of abnormally high levels of glutamate and consequently might be more vulnerable to neurodegeneration. To determine the contribution of the overactivated STN-SN pathway to the progression of PD, we studied the effect of prior unilateral STN lesion on the toxicity induced by subsequent administration of 1-methyl-4-phenyl-1,2,3,6, tetrahydropyridine (MPTP) to non-human primates. In animals from group 1, kainic-induced lesion of the STN was performed prior to the administration of MPTP whereas in animals from group 2, STN lesion was caused after animals had been chronically treated with MPTP. The lesion of the STN elicited a contralateral hemiballism in animals from group 1, and they developed an asymmetrical parkinsonism after being exposed to MPTP. The STN lesion produced an improvement in the contralateral parkinsonism and mild choreic movements in animals from group 2. Cell counting of tyrosine hydroxylase immunoreactive (TH-ir) cells was performed by stereology and showed a similar loss of TH-ir cells (approximately 85%) in the ipsilateral and contralateral SN to the lesioned STN. These data indicate that the surgical removal of the excitatory drive from the STN to SN neurons does not protect dopaminergic neurons against a chronic and extended toxic effect of MPTP and do not support the assumption that STN blockade might delay the progression of PD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16806173     DOI: 10.1016/j.expneurol.2006.04.033

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  7 in total

1.  Amantadine protects dopamine neurons by a dual action: reducing activation of microglia and inducing expression of GDNF in astroglia [corrected].

Authors:  Bernardino Ossola; Nadia Schendzielorz; Shih-Heng Chen; Gary S Bird; Raimo K Tuominen; Pekka T Männistö; Jau-Shyong Hong
Journal:  Neuropharmacology       Date:  2011-05-11       Impact factor: 5.250

2.  Blood-brain barrier permeability and brain uptake mechanism of kainic acid and dihydrokainic acid.

Authors:  Mikko Gynther; Aleksanteri Petsalo; Steen H Hansen; Lennart Bunch; Darryl S Pickering
Journal:  Neurochem Res       Date:  2014-12-09       Impact factor: 3.996

3.  Neuronal activity in the subthalamic nucleus modulates the release of dopamine in the monkey striatum.

Authors:  Yasushi Shimo; Thomas Wichmann
Journal:  Eur J Neurosci       Date:  2008-12-12       Impact factor: 3.386

Review 4.  Therapeutic potential of kainate receptors.

Authors:  Carlos Matute
Journal:  CNS Neurosci Ther       Date:  2010-12-06       Impact factor: 5.243

5.  Ceftriaxone Treatment for Neuronal Deficits: A Histological and MEMRI Study in a Rat Model of Dementia with Lewy Bodies.

Authors:  Ying-Jui Ho; Jun-Cheng Weng; Chih-Li Lin; Mei-Shiuan Shen; Hsin-Hua Li; Wen-Chieh Liao; Nu-Man Tsai; Ching-Sui Hung; Te-Jen Lai; I-Yen Lee
Journal:  Behav Neurol       Date:  2018-08-01       Impact factor: 3.342

6.  Transcription factor Six2 mediates the protection of GDNF on 6-OHDA lesioned dopaminergic neurons by regulating Smurf1 expression.

Authors:  J Gao; X-Y Kang; S Sun; L Li; B-L Zhang; Y-Q Li; D-S Gao
Journal:  Cell Death Dis       Date:  2016-05-05       Impact factor: 8.469

7.  Absence of a synergic nigral proapoptotic effect triggered by REM sleep deprivation in the rotenone model of Parkinson´s disease.

Authors:  Luana C Kmita; Jessica L Ilkiw; Lais S Rodrigues; Adriano Ds Targa; Ana Carolina D Noseda; Patrícia Dos-Santos; Juliane Fagotti; Edvaldo S Trindade; Marcelo Ms Lima
Journal:  Sleep Sci       Date:  2019 Jul-Sep
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.